The estimated Net Worth of Dimitrios Angelis is at least $1.31 Milione dollars as of 13 June 2023. Mr. Angelis owns over 28,000 units of Ameri Inc stock worth over $917,752 and over the last 10 years he sold AMRH stock worth over $393,753. In addition, he makes $0 as Independent Director at Ameri Inc.
Dimitrios has made over 5 trades of the Ameri Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 28,000 units of AMRH stock worth $215,880 on 13 June 2023.
The largest trade he's ever made was selling 28,000 units of Ameri Inc stock on 13 June 2023 worth over $215,880. On average, Dimitrios trades about 1,077 units every 42 days since 2014. As of 13 June 2023 he still owns at least 90,542 units of Ameri Inc stock.
You can see the complete history of Mr. Angelis stock trades at the bottom of the page.
Dimitrios J. Angelis J.D. serves as Independent Director of the Company. Mr. Angelis currently works with the Life Sciences Law Group, providing outside General Counsel advice to pharmaceutical, medical device and biologics companies. He is also a director of Digirad Inc. (NASDAQ: DRAD) a leader in the field of nuclear gamma cameras for use in cardiology, women’s health, pediatric and other imaging and neuropathy diagnostics applications. Previously, he has served as the Chief Executive Officer of OTI America Inc., the U.S.-based subsidiary of publicly-held On Track Innovations Ltd., a pioneer of cashless payment technology, since December 2013. His role was to oversee and monetize the extensive patent portfolio of over 100 U.S. and international patents. Mr. Angelis has served as a director of On Track Innovations since December 2012, and served as its Chairman of the Board from April 2013 until February 2015. From October 2012 until December 2013, Mr. Angelis served as the General Counsel of Wockhardt Pharmaceuticals Inc., an international biologics and pharmaceutical company. From October 2008 to October 2012, Mr. Angelis was a senior counsel at Dr. Reddy’s Laboratories, Ltd., a publicly-traded pharmaceutical company, and during 2008 he was the Chief Legal Officer and Corporate Secretary of Osteotech, Inc., a publicly-traded medical device company, with responsibility for managing the patent portfolio of approximately 42 patents. Prior to that, Mr. Angelis worked in the pharmaceutical industry in various corporate, strategic and legal roles. In addition, he worked for McKinsey & Company, Merrill Lynch and the Japanese government more than five years ago. He began his legal career as a transactional associate with the New York office of the law firm Mayer Brown. Mr. Angelis holds a B.A. degree in Philosophy and English from Boston College, an M.A. in Behavioral Science and Negotiation from California State University and a J.D. from New York University School of Law.
Dimitrios Angelis is 49, he's been the Independent Director of Ameri Inc since 2015. There are 3 older and no younger executives at Ameri Inc. The oldest executive at Ameri Holdings Inc is Thoranath Sukumaran, 67, who is the Independent Director.
Dimitrios's mailing address filed with the SEC is 1624 MARKET ST, STE 311, DENVER, CO, 80202.
Over the last 9 years, insiders at Ameri Inc have traded over $1,008,769 worth of Ameri Inc stock and bought 346,906 units worth $1,605,748 . The most active insiders traders include Edward O'donnell, Viraj J Patel e Giri Devanur. On average, Ameri Inc executives and independent directors trade stock every 25 days with the average trade being worth of $243,319. The most recent stock trade was executed by Lokesh Sikaria on 16 November 2018, trading 100,000 units of AMRH stock currently worth $30,000.
Ameri Inc executives and other stock owners filed with the SEC include: